CZ284806B6 - Podkožní implantáty na bázi derivátů nomegesrolu - Google Patents
Podkožní implantáty na bázi derivátů nomegesrolu Download PDFInfo
- Publication number
- CZ284806B6 CZ284806B6 CZ941164A CZ116494A CZ284806B6 CZ 284806 B6 CZ284806 B6 CZ 284806B6 CZ 941164 A CZ941164 A CZ 941164A CZ 116494 A CZ116494 A CZ 116494A CZ 284806 B6 CZ284806 B6 CZ 284806B6
- Authority
- CZ
- Czechia
- Prior art keywords
- implant according
- subcutaneous implant
- active ingredient
- methyl
- implants
- Prior art date
Links
- 239000007943 implant Substances 0.000 title claims abstract description 104
- 238000007920 subcutaneous administration Methods 0.000 title claims description 21
- 230000002254 contraceptive effect Effects 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 230000002035 prolonged effect Effects 0.000 title claims description 4
- 239000011159 matrix material Substances 0.000 claims abstract description 26
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 15
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 15
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 13
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 12
- -1 poly (dimethylsiloxane) Polymers 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims description 2
- 239000004621 biodegradable polymer Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- LGTNVTBMTQCJMS-BYZMTCBYSA-N (8s,9s,10r,13r,14s,17s)-17-ethyl-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1=CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 LGTNVTBMTQCJMS-BYZMTCBYSA-N 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 125000003544 oxime group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 206010033675 panniculitis Diseases 0.000 abstract description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 abstract description 3
- 239000003433 contraceptive agent Substances 0.000 abstract description 2
- 229940124558 contraceptive agent Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 21
- 229960004190 nomegestrol acetate Drugs 0.000 description 14
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 9
- 239000000186 progesterone Substances 0.000 description 9
- 229960003387 progesterone Drugs 0.000 description 9
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 229920000260 silastic Polymers 0.000 description 7
- 206010027514 Metrorrhagia Diseases 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960004400 levonorgestrel Drugs 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920003345 Elvax® Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100039875 Histone H3-7 Human genes 0.000 description 1
- 101001035307 Homo sapiens Histone H3-7 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- IWSXBCZCPVUWHT-VIFKTUCRSA-N [(8r,9s,10r,11s,13s,14s,17r)-17-acetyl-11,13-dimethyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound O=C1CC[C@@H]2[C@H]3[C@@H](C)C[C@]4(C)[C@](C(C)=O)(OC(C)=O)CC[C@H]4[C@@H]3CCC2=C1 IWSXBCZCPVUWHT-VIFKTUCRSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000005102 carbonylalkoxy group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960004911 nomegestrol Drugs 0.000 description 1
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229950010960 norgestomet Drugs 0.000 description 1
- 229960002831 norgestrienone Drugs 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940063222 provera Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920002631 room-temperature vulcanizate silicone Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9211422A FR2695826B1 (fr) | 1992-09-21 | 1992-09-21 | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ116494A3 CZ116494A3 (en) | 1995-03-15 |
| CZ284806B6 true CZ284806B6 (cs) | 1999-03-17 |
Family
ID=9433868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ941164A CZ284806B6 (cs) | 1992-09-21 | 1993-09-17 | Podkožní implantáty na bázi derivátů nomegesrolu |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5565443A (OSRAM) |
| EP (1) | EP0613372B1 (OSRAM) |
| JP (1) | JPH08506318A (OSRAM) |
| KR (1) | KR100255700B1 (OSRAM) |
| CN (1) | CN1095667C (OSRAM) |
| AP (1) | AP497A (OSRAM) |
| AT (1) | ATE198275T1 (OSRAM) |
| AU (1) | AU683423B2 (OSRAM) |
| BG (1) | BG62317B1 (OSRAM) |
| BR (1) | BR9305642A (OSRAM) |
| CA (1) | CA2122827A1 (OSRAM) |
| CZ (1) | CZ284806B6 (OSRAM) |
| DE (1) | DE69329790D1 (OSRAM) |
| DZ (1) | DZ1717A1 (OSRAM) |
| EC (1) | ECSP930986A (OSRAM) |
| FI (1) | FI942272A7 (OSRAM) |
| FR (1) | FR2695826B1 (OSRAM) |
| HU (1) | HUT67044A (OSRAM) |
| IL (1) | IL107039A (OSRAM) |
| MA (1) | MA22978A1 (OSRAM) |
| NO (1) | NO306238B1 (OSRAM) |
| OA (1) | OA09924A (OSRAM) |
| PL (1) | PL176120B1 (OSRAM) |
| RO (1) | RO115783B1 (OSRAM) |
| RU (1) | RU2120797C1 (OSRAM) |
| SK (1) | SK54694A3 (OSRAM) |
| TN (1) | TNSN93104A1 (OSRAM) |
| TW (1) | TW381024B (OSRAM) |
| WO (1) | WO1994006437A1 (OSRAM) |
| YU (1) | YU60493A (OSRAM) |
| ZA (1) | ZA936964B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660848A (en) * | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| FR2737411B1 (fr) * | 1995-08-01 | 1997-10-17 | Theramex | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
| FR2754179B1 (fr) * | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| FR2776191B1 (fr) * | 1998-03-23 | 2002-05-31 | Theramex | Composition hormonale topique a effet systemique |
| US6117441A (en) * | 1998-07-02 | 2000-09-12 | The Population Council, Inc. | Silicone core long term androgen delivery implant |
| WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| GB2355728A (en) * | 1999-10-27 | 2001-05-02 | Anson Medical Ltd | Tubular medical implants and methods of manufacture |
| WO2005039531A1 (en) | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| ES2283425T3 (es) | 2000-08-03 | 2007-11-01 | Antares Pharma Ipl Ag | Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados. |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| IL159624A0 (en) | 2001-06-29 | 2004-06-01 | Medgraft Microtech Inc | Biodegradable injectable implants and related methods of manufacture and use |
| EP1509182A4 (en) * | 2002-05-31 | 2009-12-30 | Titan Pharmaceuticals Inc | IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE |
| CA2520613C (en) | 2003-03-31 | 2012-12-04 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of dopamine agonist |
| US20050031668A1 (en) * | 2003-05-30 | 2005-02-10 | Patel Rajesh A. | Implantable polymeric device for sustained release of nalmefene |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| WO2006078320A2 (en) | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
| WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| NZ571460A (en) | 2006-04-21 | 2010-10-29 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| FR2904213B1 (fr) * | 2006-07-27 | 2008-10-10 | Creaspine Soc Par Actions Simp | Implant intervertebral destine a la fusion osseuse |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| EP2140860A1 (en) * | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
| GB2555373A (en) * | 2016-08-23 | 2018-05-02 | Reproductive Medicine And Gynaecology Associates Ltd | Implant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147783A (en) * | 1974-02-28 | 1979-04-03 | Akzona Incorporated | Oral pharmaceutical preparation |
| GB1515284A (en) * | 1974-05-21 | 1978-06-21 | Gastaud J | Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series |
| US4172132A (en) * | 1977-07-26 | 1979-10-23 | Schering Corporation | 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor |
| HU182775B (en) * | 1981-10-15 | 1984-03-28 | Richter Gedeon Vegyeszet | Process for preparing new 3-chloro-pregnane derivatives |
| US5223492A (en) * | 1987-10-27 | 1993-06-29 | Nasraoui Nejib M | Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them |
| FR2664895B1 (fr) * | 1990-07-20 | 1992-10-30 | Theramex Laboratoire | Nouveaux derives de la 6-methyl 19-nor progesterone, substitues en 3 et leur procede d'obtention. |
-
1992
- 1992-09-21 FR FR9211422A patent/FR2695826B1/fr not_active Expired - Fee Related
-
1993
- 1993-09-17 HU HU9401395A patent/HUT67044A/hu unknown
- 1993-09-17 CZ CZ941164A patent/CZ284806B6/cs not_active IP Right Cessation
- 1993-09-17 BR BR9305642A patent/BR9305642A/pt not_active Application Discontinuation
- 1993-09-17 RO RO94-00833A patent/RO115783B1/ro unknown
- 1993-09-17 RU RU94026906A patent/RU2120797C1/ru active
- 1993-09-17 AT AT93920896T patent/ATE198275T1/de not_active IP Right Cessation
- 1993-09-17 DE DE69329790T patent/DE69329790D1/de not_active Expired - Lifetime
- 1993-09-17 KR KR1019940701665A patent/KR100255700B1/ko not_active Expired - Fee Related
- 1993-09-17 SK SK546-94A patent/SK54694A3/sk unknown
- 1993-09-17 WO PCT/FR1993/000900 patent/WO1994006437A1/fr active IP Right Grant
- 1993-09-17 FI FI942272A patent/FI942272A7/fi unknown
- 1993-09-17 US US08/244,098 patent/US5565443A/en not_active Expired - Fee Related
- 1993-09-17 PL PL93303780A patent/PL176120B1/pl unknown
- 1993-09-17 CA CA002122827A patent/CA2122827A1/fr not_active Abandoned
- 1993-09-17 EP EP93920896A patent/EP0613372B1/fr not_active Expired - Lifetime
- 1993-09-17 AU AU48229/93A patent/AU683423B2/en not_active Ceased
- 1993-09-17 JP JP6507861A patent/JPH08506318A/ja active Pending
- 1993-09-20 IL IL10703993A patent/IL107039A/en not_active IP Right Cessation
- 1993-09-20 TN TNTNSN93104A patent/TNSN93104A1/fr unknown
- 1993-09-20 MA MA23291A patent/MA22978A1/fr unknown
- 1993-09-20 DZ DZ930104A patent/DZ1717A1/fr active
- 1993-09-21 YU YU60493A patent/YU60493A/sh unknown
- 1993-09-21 CN CN93114100A patent/CN1095667C/zh not_active Expired - Lifetime
- 1993-09-21 ZA ZA936964A patent/ZA936964B/xx unknown
- 1993-09-21 AP APAP/P/1993/000576A patent/AP497A/en active
- 1993-09-29 TW TW082108030A patent/TW381024B/zh not_active IP Right Cessation
- 1993-10-04 EC EC1993000986A patent/ECSP930986A/es unknown
-
1994
- 1994-05-11 OA OA60511A patent/OA09924A/fr unknown
- 1994-05-16 BG BG98776A patent/BG62317B1/bg unknown
- 1994-05-20 NO NO941900A patent/NO306238B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ284806B6 (cs) | Podkožní implantáty na bázi derivátů nomegesrolu | |
| AU741482B2 (en) | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors | |
| EA018112B1 (ru) | Вагинальная система доставки | |
| US5733565A (en) | Male contraceptive implant | |
| DE2158226A1 (de) | Arzneimittelwirkstofftraeger aus siliconkautschuk | |
| EP2062568A1 (en) | Vaginal delivery system | |
| US20150209488A1 (en) | Polymer-based surgically implatable haloperidol delivery systems and methods for their production and use | |
| RU2412693C2 (ru) | Система доставки | |
| WO2010133757A1 (en) | Vaginal delivery system | |
| EP2062569B1 (en) | Vaginal delivery system | |
| Wiranidchapong | Solid state and thermal behavior of 17β-estradiol in ammonioethyl methacrylate ester copolymer | |
| Moo-Young et al. | Patent: Male contraceptive implant | |
| HK1221634A1 (zh) | 子宫内递送系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20010917 |